ALK and non-small cell lung carcinoma: The results of our analysis showed that in the first-line treatment of patients with ALK-positive NSCLC, brigatinib had better efficacy than crizotinib and ceritinib, and there was no significant difference in terms of PFS, OS, and ORR between brigatinib and other next-generation ALK inhibitors.